
14/03/2024
Last week, the company MindMed announced the 12-week results from its Phase 2b study of MM120 (L*D D-Tartrate) in individuals with generalized anxiety disorder.
The results demonstrated that a single dose produced a clinical response in 65% of participants, with 48% of participants achieving clinical remission of symptoms. Importantly, these improvements lasted until the end of the 12-week study.
Based on these results, the FDA has granted Breakthrough Therapy Designation to MM120. This expedited review process is granted to drugs for which preliminary evidence has shown substantial improvement over existing therapies.
Uptown Research Institute is honored to have participated as a site for this Phase 2b study.
See the original press release here: https://ir.mindmed.co/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder